Send to:

Choose Destination
See comment in PubMed Commons below
Semin Hematol. 2004 Jan;41(1 Suppl 1):140-4.

Thromboelastography and recombinant factor VIIa-hemophilia and beyond.

Author information

  • 1Center for Hemophilia and Thrombosis, Department of Clinical Biochemistry, Aarhus University Hospital, Skejby Hospital, Arhaus, Denmark.


Thromboelastography (TEG), which records the continuous profiles of whole blood (WB) coagulation, can be used to evaluate the effects of hemostatic agents, such as recombinant factor VII (rFVIIa). Our group has developed a revised TEG model, involving activation with minute amounts of tissue factor and subsequent signal processing, and has used this method to evaluate the effects of rFVIIa both in patients with hemophilia and in those receiving vitamin K antagonist (VKA) thromboprophylaxis. We review the early results of our investigations, which suggest that, in clinical situations where rFVIIa has shown benefit, the changes in the profiles obtained by TEG recording appear to correlate with the clinical outcome.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk